Eli Lilly’s October 2024 research collaboration with Peptron remains strictly an evaluation-stage agreement that grants only a non-exclusive license for internal R&D on the ultrasonic spray-dried PLGA microsphere SmartDepot platform. The original 14-month term was extended in December 2025 to a maximum of 24 months, pushing the evaluation window through October 2026, with any future commercial license explicitly described as possible but not assured. No binding technology-transfer or commercialization deal has been announced despite more than 20 months of joint research, while Lilly has advanced overlapping lipid-based injectable partnerships with Camurus. With weeks remaining before the October 7 resolution and no reported progress toward a definitive license, trader consensus strongly favors “No.”
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
$11,138 ปริมาณ
$11,138 ปริมาณ
Oct 7, 2026
$11,138 ปริมาณ
$11,138 ปริมาณ
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 research collaboration with Peptron remains strictly an evaluation-stage agreement that grants only a non-exclusive license for internal R&D on the ultrasonic spray-dried PLGA microsphere SmartDepot platform. The original 14-month term was extended in December 2025 to a maximum of 24 months, pushing the evaluation window through October 2026, with any future commercial license explicitly described as possible but not assured. No binding technology-transfer or commercialization deal has been announced despite more than 20 months of joint research, while Lilly has advanced overlapping lipid-based injectable partnerships with Camurus. With weeks remaining before the October 7 resolution and no reported progress toward a definitive license, trader consensus strongly favors “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 5, 2026, 8:02 PM ET
ปริมาณการซื้อขาย
$11,138วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 research collaboration with Peptron remains strictly an evaluation-stage agreement that grants only a non-exclusive license for internal R&D on the ultrasonic spray-dried PLGA microsphere SmartDepot platform. The original 14-month term was extended in December 2025 to a maximum of 24 months, pushing the evaluation window through October 2026, with any future commercial license explicitly described as possible but not assured. No binding technology-transfer or commercialization deal has been announced despite more than 20 months of joint research, while Lilly has advanced overlapping lipid-based injectable partnerships with Camurus. With weeks remaining before the October 7 resolution and no reported progress toward a definitive license, trader consensus strongly favors “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$11,138วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 research collaboration with Peptron remains strictly an evaluation-stage agreement that grants only a non-exclusive license for internal R&D on the ultrasonic spray-dried PLGA microsphere SmartDepot platform. The original 14-month term was extended in December 2025 to a maximum of 24 months, pushing the evaluation window through October 2026, with any future commercial license explicitly described as possible but not assured. No binding technology-transfer or commercialization deal has been announced despite more than 20 months of joint research, while Lilly has advanced overlapping lipid-based injectable partnerships with Camurus. With weeks remaining before the October 7 resolution and no reported progress toward a definitive license, trader consensus strongly favors “No.”
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย